ReviewExpert review of vaccines2008
Development of multi-epitope vaccines targeting wild-type sequence p53 peptides.
Review in Expert review of vaccines, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 31 citations in OpenAlex.
- A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients.Cancer immunology, immunotherapy : CII · 2012Trial
- Oncolytic virus-mediated p53 activation boosts the antitumor immunity of a p53-transduced dendritic cell vaccine.NPJ vaccines · 2025Article
- p53 in colorectal cancer: from a master player to a privileged therapy target.Journal of translational medicine · 2025Review
- p53 at the crossroads of tumor immunity.Nature cancer · 2024Review
- Review
- IEDB and CEDAR: Two Sibling Databases to Serve the Global Scientific Community.Methods in molecular biology (Clifton, N.J.) · 2023Article
- Vaccine-Based Immunotherapy for Head and Neck Cancers.Cancers · 2021Review
- P53: A Guardian of Immunity Becomes Its Saboteur through Mutation.International journal of molecular sciences · 2020Review
- Checkpoint immunotherapy in head and neck cancers.Cancer metastasis reviews · 2017Review
- Neoantigens in immunotherapy and personalized vaccines: Implications for head and neck squamous cell carcinoma.Oral oncology · 2017Review
- Immunomodulatory Function of the Tumor Suppressor p53 in Host Immune Response and the Tumor Microenvironment.International journal of molecular sciences · 2016Review
- Dendritic cell-based autologous tumor vaccines for head and neck squamous cell carcinoma.Head & neck · 2016Article
- New perspective on targeting the tumor suppressor p53 pathway in the tumor microenvironment to enhance the efficacy of immunotherapy.Journal for immunotherapy of cancer · 2015Article
- Phase I dendritic cell p53 peptide vaccine for head and neck cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2014Article
- Recombinant modified vaccinia virus ankara (MVA) expressing wild-type human p53 induces specific antitumor CTL expansion.Cancer investigation · 2011Article
- Identification of a 17beta-hydroxysteroid dehydrogenase type 12 pseudogene as the source of a highly restricted BALB/c Meth A tumor rejection peptide.Cancer immunology, immunotherapy : CII · 2010Article
- T cell-tumor interaction directs the development of immunotherapies in head and neck cancer.Clinical & developmental immunology · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Loss of p53 tumor-suppressor function is the most common abnormality in human cancer, which can result in enhanced presentation to immune cells of wild-type (wt)-sequence peptides from tumor p53 molecules, thus providing the rationale for wt p53 peptide-based cancer vaccines. We review evidence from preclinical murine tumor models and preclinical studies that led to the clinical introduction of wt p53 peptide-based vaccines for cancer immunotherapy. Overall, this review illustrates the complex process of wt p53 epitope selection and the issues and concerns involved in the application of p53-based vaccines for patients with cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.